HK1220724A1 - 反義綴合物化合物 - Google Patents

反義綴合物化合物

Info

Publication number
HK1220724A1
HK1220724A1 HK16108771.0A HK16108771A HK1220724A1 HK 1220724 A1 HK1220724 A1 HK 1220724A1 HK 16108771 A HK16108771 A HK 16108771A HK 1220724 A1 HK1220724 A1 HK 1220724A1
Authority
HK
Hong Kong
Prior art keywords
apob
conjugate compounds
antisense conjugate
antisense
compounds
Prior art date
Application number
HK16108771.0A
Other languages
English (en)
Inventor
南納．阿爾貝克
亨里克．弗呂登倫．漢森
蘇珊．卡姆勒
瑪麗．林霍爾姆
馬克．圖爾納Ø
亨里克．奧魯姆
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2013/073859 external-priority patent/WO2014076196A1/en
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Publication of HK1220724A1 publication Critical patent/HK1220724A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
HK16108771.0A 2013-11-14 2016-07-21 反義綴合物化合物 HK1220724A1 (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2013/073859 WO2014076196A1 (en) 2012-11-15 2013-11-14 Anti apob antisense conjugate compounds
PCT/EP2013/073858 WO2014076195A1 (en) 2012-11-15 2013-11-14 Oligonucleotide conjugates
EP13192930 2013-11-14
EP14153266 2014-01-30
EP14167879 2014-05-12
PCT/EP2014/074554 WO2015071388A1 (en) 2013-11-14 2014-11-14 Apob antisense conjugate compounds

Publications (1)

Publication Number Publication Date
HK1220724A1 true HK1220724A1 (zh) 2017-05-12

Family

ID=53056817

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108771.0A HK1220724A1 (zh) 2013-11-14 2016-07-21 反義綴合物化合物

Country Status (10)

Country Link
US (1) US20160289677A1 (zh)
EP (1) EP3068885A1 (zh)
JP (1) JP2017501684A (zh)
KR (1) KR20160083876A (zh)
CN (1) CN105722980A (zh)
CA (1) CA2928349A1 (zh)
HK (1) HK1220724A1 (zh)
MX (1) MX2016005855A (zh)
RU (1) RU2016122168A (zh)
WO (1) WO2015071388A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607471T3 (es) 2002-11-18 2017-03-31 Roche Innovation Center Copenhagen A/S Diseño antisentido
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
IN2012DN00720A (zh) 2009-07-06 2015-06-19 Ontorii Inc
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
MX363068B (es) 2012-11-15 2019-03-07 Roche Innovation Ct Copenhagen As Conjugados de oligonucleotido.
PL2992009T3 (pl) 2013-05-01 2020-11-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji apolipoproteiny(a)
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
ES2812099T3 (es) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
PL3331892T3 (pl) 2015-08-06 2019-11-29 Hoffmann La Roche Sposób wytwarzania pochodnych kwasu GalNAc
US20210052631A1 (en) * 2015-09-25 2021-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
KR20180056766A (ko) * 2015-10-09 2018-05-29 웨이브 라이프 사이언시스 리미티드 뉴클레오티드 조성물 및 이의 방법
WO2017084987A1 (en) 2015-11-16 2017-05-26 F. Hoffmann-La Roche Ag GalNAc CLUSTER PHOSPHORAMIDITE
KR102468177B1 (ko) 2016-04-14 2022-11-16 에프. 호프만-라 로슈 아게 트리틸-모노-GalNAc 화합물 및 이의 용도
US20220354888A1 (en) 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
JP7048574B2 (ja) 2017-03-10 2022-04-05 国立研究開発法人国立成育医療研究センター アンチセンスオリゴヌクレオチドおよび糖原病Ｉａ型予防または治療用組成物
JOP20190215A1 (ar) * 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
JP6884268B2 (ja) * 2018-03-09 2021-06-09 第一三共株式会社 糖原病Ｉａ型治療薬
JP2023533693A (ja) * 2020-06-24 2023-08-04 サプリーム テクノロジーズ，ベー．フェー． ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用
WO2022055351A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac
WO2022055352A1 (en) * 2020-09-10 2022-03-17 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
WO2022164316A1 (en) * 2021-01-26 2022-08-04 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
CA3213673A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-27b inhibitors
WO2022200632A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-134 inhibitors
CN117642505A (zh) 2021-06-04 2024-03-01 神经微核糖核酸治疗有限公司 靶向腺苷激酶的反义寡核苷酸
EP4355369A1 (en) * 2021-06-18 2024-04-24 Sapreme Technologies B.V. Conjugate of saponin, oligonucleotide and galnac
CA3228833A1 (en) 2021-08-19 2023-02-23 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
WO2023038517A1 (en) * 2021-09-09 2023-03-16 Sapreme Technologies B.V. Semicarbazone-based saponin conjugate
CN115487308A (zh) * 2022-09-29 2022-12-20 北京大学 反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931778A2 (en) * 2005-09-15 2008-06-18 Santaris Pharma A/S RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
EP3156077B1 (en) * 2007-12-04 2022-03-09 Arbutus Biopharma Corporation Targeting lipids
EP2384197B1 (en) * 2008-12-31 2016-04-06 Roche Innovation Center Copenhagen A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
MX2011013078A (es) * 2009-06-12 2012-02-01 Santaris Pharma As Nuevos compuestos potentes antisentido anti apolipoproteina b (apob).
CA2788600C (en) * 2010-02-24 2019-12-03 Arrowhead Research Corporation Compositions for targeted delivery of sirna
CA2816155C (en) * 2010-12-17 2020-10-27 Arrowhead Research Corporation Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
CA2893801A1 (en) * 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
PL2992009T3 (pl) * 2013-05-01 2020-11-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji apolipoproteiny(a)

Also Published As

Publication number Publication date
WO2015071388A1 (en) 2015-05-21
CA2928349A1 (en) 2015-05-21
CN105722980A (zh) 2016-06-29
RU2016122168A (ru) 2017-12-19
EP3068885A1 (en) 2016-09-21
US20160289677A1 (en) 2016-10-06
JP2017501684A (ja) 2017-01-19
KR20160083876A (ko) 2016-07-12
MX2016005855A (es) 2016-07-13

Similar Documents

Publication Publication Date Title
HK1220724A1 (zh) 反義綴合物化合物
HRP20190056T1 (hr) Konjugat anti-trop2 antitijelo-lijek
HK1210213A1 (zh) 反義綴合物化合物
IL244816A0 (en) Protein-polymer-drug conjugates
IL245009A0 (en) Attach a drug from a protein and a polymer
EP2970511A4 (en) INSULIN CONJUGATES incretin
SG11201605260VA (en) Var2csa-drug conjugates
EP2928902A4 (en) conjugate compounds
PL3074449T3 (pl) Związki addycyjne poliamin
EP2968381A4 (en) MEDICAMENT CONJUGATES-SUGAR BINDING SEQUENCE
HK1202287A1 (zh) 季銨氫氧化物
HK1217202A1 (zh) 位點特異性胰島素綴合物
EP2831034A4 (en) ANTIMETASTASIC AGENTS BASED ON POLYAMINE MACROCYCLIC CONJUGATES
ZA201409119B (en) Polymer-nsaid conjugate
PL2975981T5 (pl) Ekspres do kawy
IL239381A0 (en) Espresso machine powered by hot water
GB201321335D0 (en) Top-Up
AU5187P (en) WES06 Westringia fruticosa
SG11201601843QA (en) Infusion machine
GB201319432D0 (en) Shifts
GB201315925D0 (en) Coffee machine

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE ADDRESS OF APPLICANT FROM FREMTIDSVEJ 3, 2970 HORSHOLM, GERMANY TO FREMTIDSVEJ 3, 2970 HORSHOLM, DENMARK